Nyxoah Appoints Liam Kelly as Chief Executive Officer Read more about Nyxoah Appoints Liam Kelly as Chief Executive Officer
Nyxoah Announces Chief Financial Officer Transition Read more about Nyxoah Announces Chief Financial Officer Transition
Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients Read more about Nyxoah Announces ACCCESS U.S. Pivotal Study Meets Primary Safety and Efficacy Endpoints in Complete Concentric Collapse Patients
Nyxoah Announces Pricing of $95 Million Underwritten Public Offering Read more about Nyxoah Announces Pricing of $95 Million Underwritten Public Offering
Nyxoah Announces Proposed Offering of Ordinary Shares Read more about Nyxoah Announces Proposed Offering of Ordinary Shares
Nyxoah Enters New Chapter of Long Term Value Creation Read more about Nyxoah Enters New Chapter of Long Term Value Creation
Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026 Read more about Nyxoah Announces Preliminary Results for the Fourth Quarter and Full Year 2025 and Provides Revenue Guidance for the First Quarter of 2026
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Read more about Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio Read more about Nyxoah Secures Financing Commitments of up to U.S. $77 Million to Drive U.S. Commercialization of Genio
Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea Read more about Nyxoah Receives Approval from FDA for Genio® System for the Treatment of Obstructive Sleep Apnea